BioGaia, Nestle infant formula
This article was originally published in The Tan Sheet
Executive Summary
BioGaia will provide Lactobacillus reuteri probiotic to Nestle Nutrition for use in infant formula products, the Stockholm, Sweden-based biotechnology firm says Aug. 21. BioGaia President Peter Rothschild credits the firm's probiotic safety data as "a strong factor in facilitating the agreement with Nestle," which has an existing partnership with BioGaia in the health care nutrition area. The infant formula deal will cover all world markets, excluding Korea and Japan, with an initial product launch planned for 2009
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.